Click for Philadelphia, Pennsylvania Forecast
HOME ISSUE

CALENDAR

BETWEEN ISSUES ARCHIVE DEADLINES CONTACT USFAQS
 
 
Print This Issue
Front Page
Contents
Crimes
Directory
All About Teaching
Subscribe to E-Alamanc!
Staffbox
Guidelines
 

 

Center for Clinical Epidemiology and Biostatistics:
Part of Federal Program to Research Making Better Treatment Decisions

The Center for Clinical Epidemiology and Biostatistics (CCEB), within the School of Medicine, has become part of the new Effective Health Care Program, within the federal Agency for Healthcare Research and Quality (AHRQ). The program was launched recently to help clinicians and patients determine which drugs and other medical treatments work best for certain health conditions.

The program will support the development of new scientific information through research on the outcomes of health care services and therapies, including drugs. By reviewing and synthesizing published and unpublished scientific studies, as well as identifying important issues where existing evidence is insufficient, the program will help provide clinicians and patients with better information for making treatment decisions. Initial reports from the new program will be issued this fall, with particular focus on effectiveness information relevant to Medicare beneficiaries. For information, visit the program’s website, www.effectivehealthcare.ahrq.gov.

CCEB is part of a new network of 13 Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) research centers that will conduct studies aimed at filling knowledge gaps about treatment effectiveness. Operating under strict procedures to guarantee privacy and security, DEcIDE centers will use de-identified data available through insurers, health plan, and other partner organizations to answer questions about the use, benefits, and risks of medications and other therapies. DEcIDE centers will begin work on 15 research projects immediately.

To start, CCEB researchers will examine the association between antidepressant drugs and aspiration pneumonia in the aged. “Nearly all drugs are approved based on studies comparing the new drug to a placebo,” explains Co-Principal Investigator of the Penn DEcIDE program Dr. Sean Hennessy, assistant professor of epidemiology and of pharmacology. “However, what patients and clinicians really need to know is not how well the new drug works compared with a placebo, but compared with what is already available. This lack of information on comparative effectiveness makes it very difficult to make evidence-based decisions. In the years to come, the DEcIDE Network will play a key role in addressing the need for information on comparative effectiveness. We at Penn are thrilled to be able to take part in this important effort.”

CCEB Director Dr. Brian Strom, is the principal investigator of the center. CCEB has been awarded $250,000 for their first study within the DEcIDE program.

 

 



 
  Almanac, Vol. 52, No. 7, October 11, 2005

ISSUE HIGHLIGHTS:

Tuesday,
October 11, 2005
Volume 52 Number 7
www.upenn.edu/almanac

 

top of page
Back to Contents page
HOME ISSUE CALENDAR BETWEEN ISSUES ARCHIVE DEADLINES CONTACT USFAQS